David R Minor

Summary

Affiliation: California Pacific Medical Center
Country: USA

Publications

  1. ncbi Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib
    David R Minor
    Center for Melanoma Research and Treatment, California Pacific Medical Center, San Francisco, California, USA
    Melanoma Res 22:410-1. 2012
  2. ncbi Sunitinib therapy for melanoma patients with KIT mutations
    David R Minor
    California Pacific Center for Melanoma Research and Treatment, University of California San Francisco, San Francisco, California, USA
    Clin Cancer Res 18:1457-63. 2012
  3. ncbi A phase II study of thalidomide in advanced metastatic renal cell carcinoma
    David R Minor
    California Kidney Cancer Center, California Pacific Medical Center, San Francisco, USA
    Invest New Drugs 20:389-93. 2002
  4. ncbi A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity
    David R Minor
    San Francisco Oncology Associates, California Pacific Medical Center, 2100 Webster Street 326, San Francisco, CA 94115, USA
    Cancer Biother Radiopharm 20:479-86. 2005
  5. ncbi Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis
    David R Minor
    California Pacific Medical Center, San Francisco, CA 94115, USA
    Cancer Biother Radiopharm 24:321-5. 2009
  6. ncbi Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
    David R Minor
    California Pacific Medical Center, 2100 Webster Street, Suite 326, San Francisco, California 94115, USA
    Oncologist 14:995-1002. 2009
  7. ncbi Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients
    Robert A Nagourney
    Rational Therapeutics, Inc, Long Beach, California 90806, USA
    Gynecol Oncol 88:35-9. 2003

Detail Information

Publications7

  1. ncbi Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib
    David R Minor
    Center for Melanoma Research and Treatment, California Pacific Medical Center, San Francisco, California, USA
    Melanoma Res 22:410-1. 2012
    ..Vemurafenib was tolerated at a 50% dose after a 3-week desensitization. Desensitization may be possible in patients who develop Stevens-Johnson syndrome after vemurafenib treatment...
  2. ncbi Sunitinib therapy for melanoma patients with KIT mutations
    David R Minor
    California Pacific Center for Melanoma Research and Treatment, University of California San Francisco, San Francisco, California, USA
    Clin Cancer Res 18:1457-63. 2012
    ..We aimed to assess the predictive role of KIT mutation, amplification, or overexpression for response to treatment with the kinase inhibitor sunitinib...
  3. ncbi A phase II study of thalidomide in advanced metastatic renal cell carcinoma
    David R Minor
    California Kidney Cancer Center, California Pacific Medical Center, San Francisco, USA
    Invest New Drugs 20:389-93. 2002
    ..To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy...
  4. ncbi A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity
    David R Minor
    San Francisco Oncology Associates, California Pacific Medical Center, 2100 Webster Street 326, San Francisco, CA 94115, USA
    Cancer Biother Radiopharm 20:479-86. 2005
    ..In this retrospective study, we described the relationship between achieved dose intensity and the response rate of inpatient decrescendo biochemotherapy at our center...
  5. ncbi Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis
    David R Minor
    California Pacific Medical Center, San Francisco, CA 94115, USA
    Cancer Biother Radiopharm 24:321-5. 2009
    ..Treatment with infliximab, mesalamine, and hydrocortisone enemas may produce a rapid improvement in ipilimumab-induced colitis and avoid the administration of systemic steroids...
  6. ncbi Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
    David R Minor
    California Pacific Medical Center, 2100 Webster Street, Suite 326, San Francisco, California 94115, USA
    Oncologist 14:995-1002. 2009
    ..We felt that the study of prognostic factors would determine which patients might benefit from this intensive therapy...
  7. ncbi Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients
    Robert A Nagourney
    Rational Therapeutics, Inc, Long Beach, California 90806, USA
    Gynecol Oncol 88:35-9. 2003
    ..The aim was to determine the safety and efficacy of gemcitabine plus cisplatin for patients with relapsed ovarian carcinoma and to compare ex vivo drug sensitivity profiles with clinical outcomes...